The current preclinical findings thus indicate that AR activation is associated with promotion of urothelial tumorigenesis, which is also supported by retrospective studies described above [4,5,6,7] suggesting the inhibitory effect of androgen deprivation therapy on the development and recurrence of bladder tumor. Here, AR is linked to urinary bladder neoplasm.